
Jennifer Byrne, CEO, Javara touches on why fixing clinical research requires sustained infrastructure investment and workforce development.
A nationally recognized leader and champion of the Clinical Research as a Care Option (CRAACO) movement, Jennifer Byrne’s career has been devoted to building teams and driving change in pursuit of a more efficient, more impactful approach to clinical research. In 2018, she founded Javara with a vision to revolutionize the industry by accelerating access to clinical trials for patients, sponsors, and healthcare systems alike. By bridging the gap between clinical research and clinical care, Javara enables more patients to participate through trusted point-of-care access and support. Prior to Javara, Jennifer served as CEO of PMG Research and founded Greater Gift (501(c)3). She has been recognized as a PM360 ELITE, CenterWatch Top 20 Innovator, PharmaVOICE Woman of Influence, TBJ Outstanding Woman in Business and two-time TBJ Power Player, among others. Jennifer is a graduate of Texas A&M University.

Jennifer Byrne, CEO, Javara touches on why fixing clinical research requires sustained infrastructure investment and workforce development.

Javara CEO Jennifer Byrne talks about the requirements for embedding clinical trials directly into physician practices and why solving the “last mile” of trial participation means building infrastructure at the actual point of care.

Comparing late-stage COVID-19 vaccine trials to historical practices.

Applied Clinical Trials
Survey examines issues related to clinical trials quality and participation from the patients' view.

Applied Clinical Trials
A survey from the Avoca Group examines issues related to quality of clinical trials and trial participation from the patients' view.

November 16th 2020

May 31st 2017

June 1st 2017